PMC:7795856 / 198-463 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"24","span":{"begin":7,"end":10},"obj":"Species"},{"id":"31","span":{"begin":16,"end":50},"obj":"Disease"},{"id":"32","span":{"begin":129,"end":137},"obj":"Disease"},{"id":"33","span":{"begin":138,"end":148},"obj":"Disease"},{"id":"34","span":{"begin":153,"end":159},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"Tax:10407"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D006526"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D007239"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"virus (HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":16,"end":25},"obj":"Phenotype"},{"id":"T4","span":{"begin":153,"end":159},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0012115"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"virus (HBV) and hepatitis C virus (HCV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half"}